The study authors conducted a systematic review and meta-analysis to assess the overall efficacy and safety of low-dose direct oral anticoagulants vs placebo on a background of antiplatelet therapy.
The efficacy of postoperative bridging with dalteparin vs placebo was evaluated in those with AF or mechanical heart valves when warfarin is temporarily interrupted for a surgical procedure.
Investigators report findings from the ACTION trial assessing outcomes of therapeutic vs prophylactic oral anticoagulant use among hospitalized adult patients with COVID-19 and elevated D-dimer concentration.
The longitudinal, prospective study assessed whether an association existed between MI with a silent manifestation and the occurrence of subsequent ischemic stroke.
The researchers addressed whether ziltivekimab safely and effectively reduced biomarkers of inflammation and thrombosis among patients with high cardiovascular risk and chronic kidney disease.
Researchers conducted a review of patients who were tested for COVID-19 and received aspirin or NSAIDS to assess whether aspirin was protective from death, myocardial infarction, or VTE.
The researchers sought to identify major interaction effects between clopidogrel and CYP2C19*17 status, in terms of risk for MACE and bleeding events after PCI.
The objective of this study was to test the efficacy and safety of revacept, a novel, lesion-directed antithrombotic drug, acting as a competitive antagonist to platelet glycoprotein VI.
